<DOC>
	<DOCNO>NCT01726933</DOCNO>
	<brief_summary>The aim study evaluate efficacy safety LAS41008 comparison active control placebo patient moderate severe chronic plaque psoriasis</brief_summary>
	<brief_title>LAS41008 Moderate Severe Chronic Plaque Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>1 . Signed personally date write informed consent 2 . Male / female 3 . Aged 18 year old 4 . With diagnosis chronic plaque psoriasis least 12 month enrollment study 5 . With severity psoriasis define moderate severe , reflect meeting follow criterion : PASI &gt; 10 BSA ( body surface area ) &gt; 10 % PGA moderate severe 6 . With general good health , stable medical condition consider likely interfere conduct clinical study , determine investigator base upon result medical history , laboratory result physical examination 7 . Prior therapy systemic drug psoriasis naïve systemic treatment identify candidate systemic treatment . 8 . With complete record least 12 month previous topical systemic treatment , 9 . Adhering follow washout period Topical treatment Washout Period Corticosteroids Vitamin A analogues Vitamin D analogues Anthracene derivative Tar Salicylic acid preparation 2 week Systemic treatment Biologics antipsoriatic activity 3 month Conventional systemic antipsoriatic drug phototherapy 1 month Immunosuppressive medication ( covered treatment ) Cytostatics 6 month Medications know harmful influence kidneys 5 x halftime 10 . For female childbearing potential : negative serum pregnancy test screen willing use highly effective method birth control study period 60 day last dose investigational product . Additionally must agree pregnancy test study medication . Highly effective method birth control define result low failure rate ( i.e . le 1 % per year ) use consistently correctly , implant , injectables , combine oral contraceptive , IUDs , sexual abstinence vasectomize partner . Female patient consider childbearing potential unless surgically sterilize hysterectomy bilateral tubal ligation , postmenopausal least two year . 11 . Males ( include vasectomy ) must agree use barrier contraception study medication 12 . Willing keep sun exposure reasonably constant use tan booth UV light source duration trial 1 . For female : pregnant lactate 2 . With diagnosis guttate , erythrodermic pustular psoriasis 3 . With hematological abnormality follow : platelet count &lt; 100,000/mm3 , WBC count &lt; 3,000 cells/ mm3 , lymphocyte count &lt; 1.000/µl , hemoglobin , hematocrit , red blood cell count outside 30 % upper low limit normal lab 4 . With history malignancy except non melanoma skin cancer 5 . Suffering significant gastrointestinal problem ( ulcer , diarrhea , etc . ) 6 . Known significant renal impairment 7 . Are detected abnormal liver enzymes &gt; 2x upper limit normal range 8 . With active infectious disease 9 . On systemic therapy drug may interfere investigational product take within define washout period 10 . With history alcohol drug abuse 11 . Known HIVpositive status suffer immunosuppressive disease 12 . Known hypersensitive ingredient investigational product 13 . Previous enrol study participate drug investigational trial within 30 day ( five halflives whichever longer ) prior enrolment . 14 . Not willing give consent transmission personal `` pseudonymised '' data 15 . Unable comply requirement study opinion investigator participate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>psoriasis , systemic treatment</keyword>
</DOC>